Sinomenine prevents monocrotaline-induced pulmonary arterial hypertension by inhibiting osteopontin-mediated PASMC phenotypic switching.
文献摘要
Pulmonary arterial hypertension (PAH) is a life-threatening disease driven by progressive pulmonary vascular remodeling, and aberrant phenotypic transition of pulmonary arterial smooth muscle cells (PASMCs) serves as the core pathological driver of disease deterioration. Sinomenine (SIN), a structurally defined isoquinoline alkaloid isolated from Sinomenium acutum (Thunb.) Rehder & E.H.Wilson, exhibits anti-inflammatory, vascular-protective, and anti-remodeling activities. Nevertheless, the exact molecular mechanism by which SIN regulates PASMC dysfunction to prevent PAH remains unclear. In vivo, SIN administration significantly attenuated MCT-induced PAH, right ventricular hypertrophy and pulmonary vascular remodeling in rats. In vitro, SIN effectively suppressed platelet-derived growth factor-BB (PDGF-BB)-triggered proliferation, migration and phenotypic switching of PASMCs. RNA-sequencing coupled with KEGG enrichment analysis further identified the ECM-receptor interaction pathway as the key signaling cascade dysregulated by MCT, with osteopontin (OPN) validated as the central functional target of SIN. OPN overexpression recapitulated the pro-remodeling effects of PDGF-BB in PASMCs, and such abnormal phenotypes were prevented by SIN. Molecular docking and cellular thermal shift assay demonstrated that SIN binds to NF-κB, a transcription factor of OPN, and suppresses PDGF-BB-induced NF-κB activation. This study uncovers a novel mechanism of SIN against PAH and highlights OPN as a critical mediator of its protective effects.